Tesamorelin + Ipamorelin Blends: What Buyers Verify

Tesamorelin and ipamorelin are two distinct research peptides that act on the growth hormone axis through different receptor pathways, and a "blend" means nothing more than a supplier has placed both into a single vial instead of shipping two. For a wholesale buyer, the decision that matters is not which pairing a laboratory prefers — it is whether the vial on the shelf can be independently verified once it arrives. Co-formulation makes purity attribution harder to read on a certificate of analysis, and research programs that use exercise as a variable depend on lot-to-lot consistency more than almost any other category. Real Peptides stocks Tesamorelin 10mg and Ipamorelin 10mg as separate single-compound vials, each with 99%+ HPLC purity and a publicly verifiable batch COA. All compounds are sold for research use only.

Two compounds, two receptor pathways

The reason these two get discussed together in the literature is mechanistic rather than commercial. Tesamorelin is a stabilised analogue of growth hormone-releasing hormone, studied for its activity at the GHRH receptor on the anterior pituitary. Ipamorelin belongs to a different family entirely — it is a selective growth hormone secretagogue studied at the GHS-R1a receptor, the same receptor family that endogenous ghrelin acts on. Research suggests the two pathways are complementary rather than redundant, which is why investigators designing growth hormone axis models sometimes look at them in parallel.

That distinction has a practical consequence for anyone stocking a catalog. These are structurally unrelated molecules with different amino acid sequences, different molecular weights, and different analytical signatures. A chromatogram that resolves one cleanly does not automatically resolve the other, and an assay validated for one sequence is not automatically valid for the other. When a supplier offers a combined vial, they are implicitly claiming they have handled both analytical problems at once — and that claim is the thing to test.

It is also worth being blunt about what is not known. Published work on each compound individually is more developed than published work on the pair co-formulated in a single container. Studies indicate interest in combined secretagogue models, but a buyer should not treat "blend" as a validated category simply because it appears on a price list. Treat it as a formulation choice a supplier made, and ask what supports it.

Where exercise enters the research picture

Exercise is a well-documented physiological stimulus to growth hormone secretion in the published physiology literature, which is precisely why it complicates research design involving secretagogue compounds. If exertion itself moves the endpoint being measured, then exercise is not a neutral background condition — it is a confounding variable that has to be controlled, standardised, or deliberately studied.

For a wholesale buyer, this matters less as science and more as a signal about your customer base. Laboratories and research buyers working in exercise physiology, body composition modelling, or recovery-pathway research tend to run longer studies with repeated measures. Long studies mean repeat orders against the same specification. A buyer who sells into that segment needs a supplier whose batch documentation is retrievable months after the original purchase, not a supplier whose COA was a one-time PDF attached to an invoice.

There is a second-order effect too. Research designs that involve exertion as a variable usually generate more questions back up the supply chain — questions about identity confirmation, about whether lot three matches lot one, about whether anything in the formulation changed between orders. If your supplier cannot answer those questions with a document, you end up absorbing the credibility problem yourself. That is the operational reason to care about how a blend was tested, independent of any view on the underlying science.

Nothing here constitutes guidance on how any compound should be prepared or used. Real Peptides does not provide preparation, reconstitution, or administration guidance for any catalog item; these are research-use-only materials and that guidance belongs to the qualified investigator.

Why co-formulation is a sourcing decision before it is a scientific one

Put two peptides in one container and you have created a product whose properties are not simply the sum of its parts on paper. Lyophilised peptides differ in hygroscopicity, in stability at a given storage temperature, and in how they behave once a solvent is introduced. A supplier offering a combined vial should be able to say something concrete about how the co-formulated material was handled and stored — not merely that both compounds were weighed into the same vial.

The ratio question is the one most often glossed over. A blend has a stated composition, and that composition is either verified analytically or asserted on a label. Those are very different things. If a buyer cannot see how the ratio was confirmed, the ratio is a marketing figure. Ask whether composition was measured on the finished blend or inferred from what went in.

There is also an inventory argument that rarely gets made out loud. Single-compound vials let you reorder each line independently, respond to demand that shifts between compounds, and isolate a quality problem to one SKU. A blend fixes the ratio at purchase and couples two products into one lot. If something is wrong with either component, the entire lot is affected. For a business building a catalog rather than filling a single order, that coupling is a real cost.

Reading a certificate of analysis for a combined vial

A certificate of analysis is only useful to the degree you can interpret it. On a single-compound vial, the logic is straightforward: one peptide, one main peak, a purity percentage, and an identity confirmation tying the material to the expected sequence. On a combined vial, every one of those elements needs an extra layer of explanation.

The practical test is simple. Ask the supplier to show you the chromatogram, not just the summary number, and ask which peak corresponds to which sequence. A supplier who can answer that in a sentence is running real analytics. A supplier who sends back a purity figure with no supporting trace is asking you to take it on faith.

Concentration labelling is the outer limit of what any supplier should be documenting on your behalf. Milligrams per vial is a specification. Anything beyond that — preparation steps, volumes, units — is outside what a research-use-only supplier provides, and a supplier who offers it anyway is telling you something about how they think about compliance.

The compliance questions sitting under every blend purchase

This section is informational and is not legal advice. The point is to identify the questions, not to answer them for you.

Start with labelling. Research-use-only designation has to survive the whole chain — from the supplier's label, through your own packaging and storage, into whatever documentation you give a downstream research buyer. A blend introduces a labelling question that single vials do not: what exactly is being represented, and does your own documentation accurately reflect the composition claim?

Then there are the questions only your counsel and your state board can resolve. Whether your business classification permits you to hold or resell research compounds, what records you are expected to keep, how your jurisdiction treats combined formulations as distinct from their components, and whether any registration applies to your activity — these are open questions that vary and change. Do not accept a supplier's reassurance as a substitute for your own legal review. Any vendor who tells you confidently what your state permits is overstepping.

Finally, keep your sourcing documentation defensible. The question that eventually gets asked is never "did you believe the material was pure?" It is "what did you have in writing, and can you retrieve it?" Build the habit of keeping retrievable COAs tied to lot numbers from the first order, not the first problem.

What Real Peptides does differently

Real Peptides tests every batch to 99%+ HPLC purity and runs a seven-panel analysis on each lot before it is released. Those certificates of analysis are publicly verifiable — a prospective partner can read the lab results before placing an order, rather than requesting them after the fact or paying for access. That is a deliberate break from a common industry pattern in which testing is described but never shown, or a COA is treated as a document sold separately from the product it describes.

Pricing is published to approved partners rather than quoted case by case behind a contact form. Hidden pricing is not a negotiating tactic in this category so much as a way of making comparison impossible; a buyer who cannot see tiers cannot model a catalog. Orders ship from the United States, with fulfillment in 5–7 days.

The tesamorelin and ipamorelin lines are stocked as separate single-compound vials, each with its own batch documentation and its own lot history, so a partner who wants both can order both without accepting a fixed ratio or a shared lot. The Wholesale Partner Program application is a three-step process: submit your business details, get reviewed for approval, and receive partner pricing access.

All compounds are supplied for laboratory research use only. They are not FDA-approved drugs and are not supplied for human or veterinary use.

If you are stocking this category

A buyer who is evaluating growth hormone secretagogue research compounds for a catalog should be able to see purity data before committing, order components independently, and retrieve lot documentation months later. If your current supplier fails any of those three tests, the Wholesale Partner Program application is the place to start — business details, review, pricing access.

Related reading on the catalog includes the Performance & Recovery Research and Growth Factor & Tissue Signaling Research collections, alongside the broader Popular Peptides range and individual compounds such as CJC-1295 No DAC 10mg.